AACR logo

More articles from Pharmacokinetics and Pharmacodynamics

Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors
Albert A Antolin, Malaka Ameratunga, Udai Banerji, Paul Clarke, Paul Workman, Bissan Al-Lazikani

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-C01; DOI: 10.1158/1535-7163.TARG-19-LB-C01
Abstract C009: Clinical pharmacokinetic and pharmacodynamic analyses support biological effectivity of the PARP inhibitor olaparib as radiosensitizer at low doses
Rosemarie de Haan, Dick Pluim, Manon Verwijs, Gabe Sonke, Michel van den Heuvel, Baukelien van Triest, Marcel Verheij, Conchita Vens

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C009; DOI: 10.1158/1535-7163.TARG-19-C009
Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers
Eunice Yuen, Robert Bell, Maria Posada, Christophe Massard, Jordi Rodon, Claire Smith, Katharine Thorn, JT Diener, Demetrio Ortega, Jeffrey Suico, Karim Benhadji

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B083; DOI: 10.1158/1535-7163.TARG-17-B083
Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor
Deborah Knoerzer, Martin Teresk, Peter Krutzik, Erika O’Donnell, Gary DeCrescenzo, Dean Welsch, Caroline Emery

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B085; DOI: 10.1158/1535-7163.TARG-17-B085
Abstract B081: Elucidating the pharmacodynamics of PI3K and Ras-Raf signaling through isoform-specific multiplexed quantification of downstream effector phosphorylation
William G. Herrick, Casey L. Kilpatrick, Melinda Hollingshead, James H. Doroshow, Ralph E. Parchment, Apurva K. Srivastava

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B081; DOI: 10.1158/1535-7163.TARG-17-B081
Abstract B082: Evaluation of the effects of an oral Notch inhibitor, LY3039478, on QT interval, and absolute and pilot relative bioavailability studies conducted in healthy subjects
Eunice Yuen, Maria Posada, Claire Smith, Katharine Thorn, Dale Greenwood, Michelle Burgess, Karim Benhadji, Demetrio Ortega, Louise Chinchen, Jeffrey Suico

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B082; DOI: 10.1158/1535-7163.TARG-17-B082
Abstract B084: Preclinical pharmacokinetic evaluation of alofanib for cancer treatment
Ilya Tsimafeyeu, Mikhail Byakhov, Vlatka Bencetić Mihaljević, Jasna Padovan, Genoveva Murillo, Nadezhda Dragun, Evgenia Gavrilova, Sergei Tjulandin

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B084; DOI: 10.1158/1535-7163.TARG-17-B084
Abstract B152: Clinical pharmacokinetics of an improved tablet formulation of ONT-380 in HER2+ metastatic breast cancer patients
Alex C. Vo, Luke Walker, Diana Hausman, Scott Peterson

Molecular Cancer Therapeutics Dec 2015, 14 (12 Supplement 2) B152; DOI: 10.1158/1535-7163.TARG-15-B152
Abstract B144: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study
Jason M. Summa, Daniel D. Von Hoff, Jasgit C. Sachdev, Monica M. Mita, Patricia M. LoRusso, Peter D. Eisenberg, Howard A. Burris, Lowell L. Hart, Hagop Youssoufian, Donald M. Parsons, Susan C. Low

Molecular Cancer Therapeutics Dec 2015, 14 (12 Supplement 2) B144; DOI: 10.1158/1535-7163.TARG-15-B144
Abstract B150: Identifying tolerable schedules for targeted anti-cancer agents by applying ordered logistic regression modeling to empirical pathology scores in mice
Francis Gibbons, Shenghua Wen, Prasad Nadella

Molecular Cancer Therapeutics Dec 2015, 14 (12 Supplement 2) B150; DOI: 10.1158/1535-7163.TARG-15-B150

Main menu

User menu

Search

More articles from Pharmacokinetics and Pharmacodynamics

Pages

Articles

Info for

About MCT